Benzinga - by Lisa Levin, Benzinga Editor.
Abbott Laboratories (NYSE: ABT) reported better-than-expected third-quarter results.
Abbott reported quarterly adjusted EPS of $1.14, compared to $1.15 a year ago, beating the consensus of $1.04. Sales of $10.1 billion decreased 2.6%, beating the consensus of $9.32 billion.
Abbott said it sees FY23 adjusted EPS of $4.42-$4.46 versus prior guidance of $4.30-$4.50 and consensus of $4.18.
Abbott shares fell 0.1% to trade at $95.51 on Thursday.
These analysts made changes to their price targets on Abbott following earnings announcement.
- Raymond James cut the price target on Abbott from $123 to $110. Raymond James analyst Jayson Bedford maintained an Outperform rating.
- Wells Fargo lowered the price target on Abbott from $136 to $116. Wells Fargo analyst Lawrence Biegelsen maintained an Overweight rating.
- Morgan Stanley slashed the price target on Abbott from $112 to $107. Morgan Stanley analyst David Lewis maintained an Equal-Weight rating.
Latest Ratings for ABT
Jan 2022 | Morgan Stanley | Maintains | Overweight | |
Jan 2022 | Raymond James | Maintains | Outperform | |
Jan 2022 | Morgan Stanley | Maintains | Overweight |
View the Latest Analyst Ratings
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.